Clinical Trial Update: Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating netarsudil to prevent corticosteroid-induced intraocular pressure elevation; trial completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Keratopathy
• Fuchs Endothelial Dystrophy

Drugs mentioned

• Netarsudil (netarsudil)

Snippet

Sponsor: Cornea Research Foundation of America | Conditions: Fuchs' Endothelial Dystrophy, Bullous Keratopathy | Phase 3 | Status: COMPLETED | Results posted: 2021-02-12